NeuroSigma, Inc., a bioelectronics company based in Los Angeles, has finalized a significant investment of approximately $1 million to enhance the manufacturing capabilities for its innovative ADHD treatment device. The funding, aimed at high-volume production, comes as part of a collaboration with Singapore-based Armstrong Asia.
This strategic investment, led by Pasadena’s Checkmate Capital, will support the development of the second-generation Monarch external Trigeminal Nerve Stimulation (eTNS) device. Designed to treat pediatric attention-deficit/hyperactivity disorder (ADHD), the new device is expected to launch in the first quarter of 2026, following the successful pilot commercialization of its first-generation model in November 2025.
Manufacturing and Market Strategy
The funds will facilitate a cost-efficient manufacturing process, enabling NeuroSigma to meet the anticipated demand for the Monarch eTNS device. Dr. Colin Kealey, president and chief executive officer of NeuroSigma, expressed optimism about the company’s collaboration with Armstrong Asia, stating, “This investment enables cost-efficient and scalable manufacturing of the second-generation Monarch eTNS device. As we move into 2026, we look forward to delivering this innovative product to patients and families throughout the world.”
The first-generation Monarch eTNS System made history as the first wearable medical device to receive FDA clearance as a drug-free treatment for ADHD. The upcoming second-generation device retains the core technology of trigeminal nerve stimulation while offering a more user-friendly interface.
Industry Insights and Future Prospects
The investment is part of a broader initiative between Armstrong Asia and Checkmate Capital, which focuses on cross-border transactions in life sciences and medical technology. Tom Paschall, chief executive of Checkmate Capital and a director at NeuroSigma, highlighted the favorable conditions in the external neurostimulation sector, stating, “The Monarch eTNS device is a groundbreaking neuro-electronic product that provides patients, families, and physicians with an alternative to stimulant medications and the negative side effects associated with them.”
As NeuroSigma prepares for the launch, the company is well-positioned to address a growing market need for effective ADHD treatments that do not rely on traditional pharmaceuticals. With the backing of strategic partners and a commitment to innovative technology, NeuroSigma aims to make a significant impact in the medical device landscape.
Information for this article was sourced from NeuroSigma and Armstrong Asia.
